ALB and fatty liver disease: As shown in Fig. 3, glucose tolerance was significantly lower in Alb-Cre x E47flox/flox (E47ΔLKO) mutants in response to Dex treatment (Fig. 3a, Supplementary Fig. 3B), and liver histology as well as liver and plasma triglyceride measurements showed protection from hepatic steatosis and dyslipidemia in Cort treated mice (Fig. 3b and c).